Sangamo Therapeutics Inc
sangamo.comWhat Do They Do?
Develops gene therapies and gene-regulation treatments for neurological and rare diseases, and licenses gene-delivery and gene-editing technology to biopharmaceutical companies.
10-K for FY2025, filed Mar 30, 2026We are a genomic medicine company committed to translating ground-breaking science into medicines that transform the lives of patients and…View ↗
Our neurology development is focused on two innovative areas: (i) development of epigenetic regulation therapies to treat serious…View ↗
In addition, we are party to collaboration and license arrangements pursuant to which our collaborators are developing preclinical product…View ↗
We also are developing novel engineered AAV capsids enhanced for delivery to neurological targets and have identified a proprietary…View ↗
Isaralgagene civaparvovec, also known as ST-920, our wholly owned gene therapy product candidate for the treatment of Fabry disease, was…View ↗
We are also developing next generation modular integrase technology, engineered to enable large-scale genome editing. Building on our deep…View ↗
How Do They Make Money?
Biopharmaceutical partners pay upfront fees for licenses, research-service charges and reimbursements, with additional milestone, target-selection, sublicense and royalty payments. A separate license fee is paid when the license takes effect; research work is paid as the work is done.
10-K for FY2025, filed Mar 30, 2026
$39.6M
-
10-K for FY2025, filed Mar 30, 2026
$39.6M ↗
Who Are Their Customers?
Biopharmaceutical companies enter collaboration and license agreements with Sangamo to develop product candidates and use its gene-delivery and gene-editing platforms.
10-K for FY2025, filed Mar 30, 2026In addition, we are party to collaboration and license arrangements pursuant to which our collaborators are developing preclinical product…View ↗
We also are developing novel engineered AAV capsids enhanced for delivery to neurological targets and have identified a proprietary…View ↗
Collaborations and LicensesView ↗
Do Revenues Turn Into Profits?
No. It lost $122.9M in FY2025.
10-K for FY2025, filed Mar 30, 2026
−$121.2MView ↗
10-K for FY2025, filed Mar 30, 2026
−$122.9MView ↗
10-K for FY2025, filed Mar 30, 2026
−$97.3MView ↗
How Are They Changing?
- Net income
-
Sources
10-Q for Q1 FY2026, filed May 14, 2026
−$31MView ↗
- ▲ +1% (Loss)
- vs −$30.6M in Q1 FY2025
-
Sep 2, 2026
Lilly completed its purchase of Sangamo technology platforms and the prion program
The sale brought $50 million in cash and included assumption of certain specified liabilities.
Sources
8-K, filed Sep 8, 2026
On August 20, 2026, the Court entered a Sale Order authorizing the sale of the Lilly Assets pursuant to the terms of the Asset Purchase…View ↗
-
Aug 28, 2026
PTC agreed to buy Sangamo’s Fabry disease program
The agreement provides for $111,000,000 in cash at closing and up to $100,000,000 in milestone payments.
Sources
8-K, filed Aug 28, 2026
On August 25, 2026, the Company entered into an Asset Purchase Agreement (the “PTC APA”) with PTC, pursuant to which the Company has agreed…View ↗
-
Jul 20, 2026
Nasdaq denied Sangamo’s request to remain listed
Sangamo’s stock was suspended from Nasdaq and moved to the OTCID Basic Market.
Sources
8-K, filed Jul 20, 2026
On July 14, 2026, the Company received a written determination letter (the “Letter”) from the Nasdaq Hearings Panel (the “Panel”) of the…View ↗
-
Jun 23, 2026
Sangamo filed for Chapter 11 bankruptcy protection
It continued operating under court supervision and had agreed to sell technology platforms to Lilly for $50 million.
Sources
8-K, filed Jun 23, 2026
On June 23, 2026 (the “Petition Date”), Sangamo Therapeutics, Inc. (the “Company”) filed a voluntary petition (Case No. 26-10989) for…View ↗
Shrinking. Revenue fell 64% in 4 years, from $110.7M in FY2021 to $39.6M in FY2025, about 23% a year.
A narrower focus on neurology
The older report described gene therapy, engineered cell therapies and genome engineering across programs for Fabry disease, kidney transplant rejection, hemophilia A and sickle cell disease. The latest report centers development on neurological gene-regulation therapies and engineered delivery capsids, while retaining clinical programs for Fabry disease and hemophilia A.
10-K for FY2022, filed Feb 23, 2023 10-K for FY2025, filed Mar 30, 2026Our neurology development is focused on two innovative areas: (i) development of epigenetic regulation therapies to treat serious…View ↗
We also are developing novel engineered AAV capsids enhanced for delivery to neurological targets and have identified a proprietary…View ↗
Isaralgagene civaparvovec, also known as ST-920, our wholly owned gene therapy product candidate for the treatment of Fabry disease, was…View ↗
We are also evaluating several potential routes of administration for our neurology-targeted investigational therapies, as delivery of…View ↗
Who Do They Compete With?
Competes with F. Hoffman-LaRoche, Protalix Biotherapeutics, Sanofi, BioMarin Pharmaceutical, Spark Therapeutics, Spur Therapeutics, Exegenesis Bio, 4D Molecular Therapeutics, Caribou Biosciences, CRISPR Therapeutics, Editas Medicine, Intellia Therapeutics, Beam Therapeutics, Cellectis, Precision BioSciences, Alnylam Pharmaceuticals, Ionis Pharmaceuticals, Moderna, Regulus Therapeutics, and Voyager Therapeutics
10-K for FY2025, filed Mar 30, 2026Protein pharmaceuticals under development at pharmaceutical and biotechnology companies such as F. Hoffman-LaRoche Ltd., Protalix…View ↗
Loading...
